EAPA Litigation

Under the Enforce and Protect Act, CBP investigates whether a company is evading particular antidumping and countervailing duty orders. Litigation on determinations made under the relatively new statute have centered on due process protections for respondents, CBP's evidentiary basis for its decisions and the interplay of decisions made on the scope of the applicable AD/CVD orders from both CBP and the Commerce Department. The Court of Appeals for the Federal Circuit issued a key decision for all EAPA cases in Royal Brush Manufacturing v. United States, when it found CBP to have violated a respondent's due process protections by failing to provide it with access to the business proprietary information used in the proceeding.

Date Range:

Author:

Topic:

Refine Category Search

Clear Terms

Search Primer

Multi-word term: Place inside quotes to ensure an exact match together (e.g. "China import").

Term list: Separate terms with spaces, not commas or semicolons to find either word (e.g. AD/CVD antidumping).

Acronyms: Use all capital letters (e.g., ACE).

Required term: If a term must be included in any resulting articles, prefix it with a plus sign (e.g., CBP +releases).

Excluded term: If a term should be excluded from any articles being found, prefix it with a minus sign (e.g., -ruling).

Singular form: Use the singular form when doing multi-word terms (e.g. "russian export control" instead of "russian export controls").

Shortest word form: When you have different word forms in a quoted term, include the shortest version if it is the last part of the expression (e.g., "entity list" instead of "entity listing" or "entity listed").

New and Revised FDA Import Alerts for Jan. 13

January 14, 2015 |FDA

On Jan. 13 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:

New and Revised FDA Import Alerts for Dec. 22

January 13, 2015 |FDA

On Dec. 22 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:

New and Revised FDA Import Alerts for Jan. 9

January 12, 2015 |FDA

On Jan. 9 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:

New and Revised FDA Import Alerts for Jan. 8

January 9, 2015 |FDA

On Jan. 8 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:

FDA Enforcement Report on Recalls & Field Corrections for Jan. 7

January 9, 2015 |FDA

The Food and Drug Administration issued its weekly Enforcement Report for Jan. 7 that lists the status of recalls and field corrections for food, drugs, biologics, and devices (here). The report covers both domestic and foreign firms.

New and Revised FDA Import Alerts for Jan. 6

January 7, 2015 |FDA

On Jan. 6 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:

New and Revised FDA Import Alerts for Jan. 5

January 6, 2015 by Brian Feito|FDA

On Jan. 5 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of:

FDA Warns New York Seafood Importer of HACCP Violations

January 6, 2015 |FDA

A New York-based seafood importer faces a ban on its imports of fish and fishery products, said the Food and Drug Administration in a warning letter dated Dec. 8 (here). The agency said an inspection of Yandi New York Trading Co. Ltd.’s Brooklyn, New York facility turned up violations of seafood hazard analysis and critical control point (HACCP) regulations in the company’s imported dried anchovies. If the violations aren’t corrected, FDA says it will place the company’s seafood imports on detention without physical examination. FDA also said it may assess fees for the cost of any reinspection to verify the importer has brought itself into compliance.

FDA Threatens Import Refusal for Chinese Pharmaceutical Facility

January 6, 2015 |FDA

The Food and Drug Administration may refuse imports of pharmaceuticals manufactured at a Chinese facility because of violations of current good manufacturing practice requirements, it said in a warning letter dated Dec. 19 (here). The agency said its inspectors found the violations in manufacturing procedures for finished pharmaceuticals and active pharmaceutical ingredients during a tour of Novacyl Wuxi Pharmaceutical Co., Ltd.’s facility in Wuxi, China. Unless they are corrected, FDA may place products from the facility on import alert and detention without physical examination, it said.

New and Revised FDA Import Alerts for Jan. 2

January 5, 2015 |FDA

On Jan. 2 the Food and Drug Administration posted new and revised versions of the following Import Alerts on the detention without physical examination of: